Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HEMACORD (New York Blood Center)
- Development stage
- Unknown
- Lead developer
- New York Blood Center
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
HEMACORD is an allogeneic hematopoietic stem cell therapy derived from human umbilical cord blood, developed by the New York Blood Center's National Cord Blood Program. It was the first hematopoietic progenitor cell (HPC) therapy to receive FDA approval. The product consists of hematopoietic progenitor cells, which, after intravenous infusion, migrate to the bone marrow where they engraft and differentiate into mature blood cells (erythrocytes, leukocytes, and platelets). This process, known as hematopoietic reconstitution, is used to treat patients with hematologic malignancies such as leukemia and lymphoma, myelodysplastic syndromes, bone marrow failure syndromes like severe aplastic anemia, and various inherited metabolic or immune system genetic diseases. HEMACORD provides a vital alternative for patients who lack a HLA-matched related donor.
- Brand names
- HEMACORD
- Other names
- Umbilical Cord Blood Transplantation-New York Blood Center-leukemia-lymphoma-myelodysplasia-severe aplastic anemia-genetic diseaseNew York Blood Center National Cord Blood ProgramHPC, Cord Blood, New York Blood CenterAllogeneic Umbilical Cord Blood
Beyond the preview
Go deeper on HEMACORD (New York Blood Center).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HEMACORD (New York Blood Center).